prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
=== Conventional lethal injection protocol === Typically, three drugs are used in lethal injection and are administered in the following order: midazolam for sedation, pancuronium bromide (Pavulon) is used to cause muscle paralysis and decreased neural transmission to the lungs, and potassium chloride to stop the heart.
=== Nanorecording === In a nanorecording application, a certain rotaxane is deposited as a Langmuir–Blodgett film on ITO-coated glass. When a positive voltage is applied with the tip of a scanning tunneling microscope probe, the rotaxane rings in the tip area switch to a different part of the dumbbell and the resulting new conformation makes the molecules stick out 0.3 nanometer from the surface. This height difference is sufficient for a memory dot. It is not yet known how to erase such a nanorecording film.
== Research == Zalsupindole, as well as related drugs such as tabernanthalog (TBG; DLX-007), DLX-159, DLX-2270, and JRT, are licensed by Delix Therapeutics and are being developed for treatment of neuropsychiatric disorders such as depression and schizophrenia. As of January 2026, zalsupindole is in phase 1 clinical trials for major depressive disorder and other central nervous system disorders. Phase 1a and 1b trials have been completed and results reported. A phase 2 trial is being planned and has been cleared by the FDA for at home administration.
Before showing the documents to Sports Illustrated, Exum tried to use them in a lawsuit against USOC, accusing the organization of racial discrimination and wrongful termination against him and cover-up over the failed tests. the Denver federal Court summarily dismissed his case for lack of evidence. The USOC labelled his case "baseless" as he himself was the one in charge of screening the anti-doping test program of the organization and clarifying that the athletes were cleared according to the rules. Carl Lewis broke his silence on allegations that he was the beneficiary of a drugs cover-up, admitting he had failed tests for banned substances, but claiming he was just one of "hundreds" of American athletes who were allowed to escape bans, concealed by the USOC. Lewis has acknowledged that he failed three tests during the 1988 US Olympic trials, which under international rules at the time should have prevented him from competing in the 1988 Summer Olympics. Former athletes and officials came out against the USOC cover-up. "For so many years I lived it. I knew this was going on, but there's absolutely nothing you can do as an athlete. You have to believe governing bodies are doing what they are supposed to do. And it is obvious they did not," said former American sprinter and 1984 Olympic champion, Evelyn Ashford. Exum's documents revealed that Carl Lewis had tested positive three times at the 1988 Olympics trials for minimum amounts of pseudoephedrine, ephedrine, and phenylpropanolamine, which were banned stimulants. Bronchodilators are also found in cold medication.
== Algorithm == The Chou–Fasman method predicts helices and strands in a similar fashion, first searching linearly through the sequence for a "nucleation" region of high helix or strand probability and then extending the region until a subsequent four-residue window carries a probability of less than 1. As originally described, four out of any six contiguous amino acids were sufficient to nucleate helix, and three out of any contiguous five were sufficient for a sheet. The probability thresholds for helix and strand nucleations are constant but not necessarily equal; originally 1.03 was set as the helix cutoff and 1.00 for the strand cutoff. Turns are also evaluated in four-residue windows, but are calculated using a multi-step procedure because many turn regions contain amino acids that could also appear in helix or sheet regions. Four-residue turns also have their own characteristic amino acids; proline and glycine are both common in turns. A turn is predicted only if the turn probability is greater than the helix or sheet probabilities and a probability value based on the positions of particular amino acids in the turn exceeds a predetermined threshold. The turn probability p(t) is determined as:
Sources: en.wikipedia.org
Sadat became increasingly wary of Libya's radical direction, and the September 1973 deadline for implementing the Federation passed with no action taken. After the 1969 coup, representatives of the Four Powers—France, the UK, the US, and the Soviet Union—were called to meet RCC representatives. The UK and the US quickly extended diplomatic recognition, hoping to secure their military bases and fearing further instability. Hoping to ingratiate themselves with Gaddafi, in 1970 the US informed him of at least one planned counter-coup. Such attempts to form a working relationship with the RCC failed; Gaddafi was determined to reassert national sovereignty and expunge what he described as foreign colonial and imperialist influences. His administration insisted that the US and the UK remove their military bases from Libya. The British left in March and the Americans in June 1970. Moving to reduce Italian influence, in October 1970 all Italian-owned assets were expropriated, and the 12,000-strong Italian community was expelled alongside the smaller community of Libyan Jews. The day became a national holiday known as "Vengeance Day". Italy complained that this was in contravention of the 1956 Italo-Libyan Treaty, although no UN sanctions came. Aiming to reduce NATO power in the Mediterranean, in 1971 Libya requested that Malta cease allowing NATO to use its land for a military base, in turn offering Malta foreign aid. Compromising, Malta's government continued allowing NATO to use the island, but only on the condition that NATO would not use it for attacks on Arab territory.
=== M–Mey === Ida Maclean (1877–1944). British biochemist at the Lister Institute of Preventive Medicine, known work on fatty acids in animals and fat synthesis. John Macleod FRS (1876–1935). British biochemist and physiologist at the University of Toronto, discoverer of insulin. Nobel Prize in Physiology or Medicine (1923). Thaddeus Mann FRS (1908–1993). Ukrainian-British biochemist at the University of Cambridge, who worked on reproductive biology. Bengt Mannervik (b. 1943). Swedish biochemist at Stockholm University known for work on enzymes related to glutathione metabolism. Emanuel Margoliash (1920–2008). Israeli-American biochemist at Northwestern University, known for research on cytochrome c sequences, which formed the starting point for studies of protein evolution. Member Natl. Acad. Sci. USA. Vincent Massey FRS (1926–2002). Australian biochemist and enzymologist at the University of Michigan, best known for studies of flavoenzymes. Member Natl. Acad. Sci. USA. Elmer Verner McCollum (1879–1967). American biochemist at Johns Hopkins University, who discovered Vitamins A and D, and their benefits. Member Natl. Acad. Sci. USA. Harden M. McConnell (1927–2014). American biochemist at Stanford known for the technique of spin-labels, whereby electron and nuclear magnetic resonance can be used to study the structure and kinetics of proteins. Member Natl. Acad. Sci. USA. William D. McElroy (1917–1999). American biochemist and science administrator at University of California San Diego. Member Natl. Acad. Sci. USA. Enrique Meléndez-Hevia (born 1946).
=== Flow: Sverdrup === One sverdrup (Sv) is equal to 1,000,000 cubic metres per second (264,000,000 USgal/s). It is used almost exclusively in oceanography to measure the volumetric rate of transport of ocean currents.
If the target DNA contains an allele complementary to the probe's 3’ base, the target DNA will completely hybridize to the probe, allowing DNA polymerase to extend from the 3’ end of the probe. This is detected by the incorporation of the fluorescently labeled dNTPs onto the end of the probe. If the target DNA does not contain an allele complementary to the probe's 3’ base, the target DNA will produce a mismatch at the 3’ end of the probe and DNA polymerase will not be able to extend from the 3' end of the probe. The benefit of the second approach is that several labeled dNTPs may get incorporated into the growing strand, allowing for increased signal. However, DNA polymerase in some rare cases, can extend from mismatched 3’ probes giving a false positive result. A different approach is used by Sequenom's iPLEX SNP genotyping method, which uses a MassARRAY mass spectrometer. Extension probes are designed in such a way that 40 different SNP assays can be amplified and analyzed in a PCR cocktail. The extension reaction uses ddNTPs as above, but the detection of the SNP allele is dependent on the actual mass of the extension product and not on a fluorescent molecule. This method is for low to medium high throughput, and is not intended for whole genome scanning. The flexibility and specificity of primer extension make it amenable to high throughput analysis. Primer extension probes can be arrayed on slides allowing for many SNPs to be genotyped at once.
Sources: en.wikipedia.org
== History == In 1889, German physiologist Max Verworn applied a low-level direct current to a mixture of bacterial species and observed that some moved toward the anode and others moved to the cathode. Two years later, in 1891, Belgian microscopist E. Dineur made the first known report of vertebrate cells migrating directionally in a direct current, a phenomenon which he coined galvanotaxis. Dineur used a zinc–copper cell to apply a constant current to the abdominal cavity of a frog via a pair of platinum electrodes. He found that inflammatory leukocytes aggregated at the negative electrode. Since these pioneering studies, a variety of different cell types and organisms have been shown to respond to electric fields.
== Local terms == The National Commission for Enterprises in the Unorganized Sector (NCEUS) defines Unorganized sector as 'Unorganized Sector is a Sector consisting of all unincorporated private enterprises owned by individuals or households engaged in the sale or production of goods and services operated on a proprietary or partnership basis and with less than ten total workers.' Based on this definition, Organized sector in India is defined as 'Organized sector is a sector consisting of all incorporated enterprises which are engaged in the sales or production of goods and services operated as private limited or limited organizations governed by Companies act and having more than ten total workers.' With this definition, Organized Retail Sector will be characterized as:
Lindow Moss is a peat bog in Lindow, an area of Wilmslow, Cheshire, which has been used as common land since the medieval period. It formed after the last ice age, one of many such peat bogs in north-east Cheshire and the Mersey basin that formed in hollows caused by melting ice. Investigations have not yet discovered settlement or agricultural activity around the edge of Lindow Moss that would have been contemporary with Lindow Man, but analysis of pollen in the peat suggests there was some cultivation in the vicinity. Once covering over 600 hectares (1,500 acres), the bog has now shrunk to a tenth of its original size. It is a dangerous place and an 18th-century writer recorded people drowning there. For centuries, the peat from the bog was used as fuel, and it continued to be extracted until the 1980s, by which time the process had been mechanised. Lindow Moss is a lowland raised mire, a type of peat bog which often produces the best-preserved bog bodies, allowing more detailed analysis. Lowland raised mires occur mainly in northern England and extend south to the Midlands. Lindow Man is one of 27 bodies to be recovered from such areas.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.